Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study
Authors' conclusion
The use of nirmatrelvir-ritonavir may be preferred to molnupiravir for COVID-19 patients with T2DM and without contraindication to either treatment.
Study context
- Population
- Adults aged ≥18 years with T2D and COVID-19 who received molnupiravir or nirmatrelvir-ritonavir within 5 days of infection, 16 March 2022–31 December 2022, non-hospital and hospital settings, Hong Kong17,974 non-hospitalized
- Comparison
- Nirmatrelvir-ritonavir vs molnupiravir
- Outcome
- All-cause mortality, non-hospitalized
- Follow-up
- 28 days
Methodological detailssequential trial approach, one-to-one propensity-score matched, territory-wide electronic health records
- Sequential trial approach
- One-to-one propensity-score matched
- Territory-wide electronic health records
Main finding
As reported in the abstract
Nirmatrelvir-ritonavir vs MolnupiravirHazard ratio (95% CI)
All-cause mortality, non-hospitalized
0.47(0.30–0.73)
- Lower risk with nirmatrelvir-ritonavir
- absolute risk reduction 0.80 % (95% CI 0.56–1.04)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Hospitalization, non-hospitalized · 28 daysNirmatrelvir-ritonavirvs Molnupiravir | 0.73 (0.66–0.82) | |
| All-cause mortality, hospitalized · 28 daysNirmatrelvir-ritonavirvs Molnupiravir | 0.56 (0.40–0.80) | |
| 0.512Hazard ratio (log scale) |
| Outcome | Absolute risk reduction (%) (95% CI) |
|---|---|
| Hospitalization, non-hospitalized · 28 daysNirmatrelvir-ritonavir vs Molnupiravir · lower risk with nirmatrelvir-ritonavir | 4.01 (3.19–4.83) |
| All-cause mortality, hospitalized · 28 daysNirmatrelvir-ritonavir vs Molnupiravir · reduced risk with nirmatrelvir-ritonavir | 2.94 (1.65–4.23) |
Subgroups (age, sex, Charlson comorbidity index, vaccine doses)
- Consistent findings across all subgroups
Original publication
Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study. Diabetes Obes Metab. Published 7 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →